HR+/HER2- Advanced Breast Cancer: How the latest survival data can help to inform your choice of CDK4/6 inhibitor
21 May 2024
Keynote Theatre | Early Diagnosis and Screening Focus Day
![HR+/HER2- Advanced Breast Cancer: How the latest survival data can help to inform your choice of CDK4/6 inhibitor](https://taskfilescsm.s3.amazonaws.com:443/uploads/speaker_thumb/2024-05-0211%253A26%253A26065123-Novartis.jpg)
This promotional symposium has been organised and funded by Novartis Pharmaceuticals UK Ltd and is intended for UK Healthcare Professionals only. Novartis products will be discussed at this meeting and Prescribing Information for all relevant Novartis medicines will be available during the meeting.
440039 I May 2024